CN103157095B - Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof - Google Patents
Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof Download PDFInfo
- Publication number
- CN103157095B CN103157095B CN201310056588.8A CN201310056588A CN103157095B CN 103157095 B CN103157095 B CN 103157095B CN 201310056588 A CN201310056588 A CN 201310056588A CN 103157095 B CN103157095 B CN 103157095B
- Authority
- CN
- China
- Prior art keywords
- semen phaseoli
- gram
- dry powder
- phaseoli vulgaris
- stachyose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses kidney bean phytolectin applications in preparation of human drugs and a drug composition, and belongs to the technical field of drugs. Kidney bean phytolectins are used as active components for preparing drugs used for adding lactobacillus amounts in woman vaginas. The drug composition adopts the kidney bean phytolectins, tremella polysaccharide, stachyose or/and raffinose and bletilla gum, or added scutellaria, Hollygreen Barberry and matrine extraction as the active components. The drug composition comprises relative weight parts of that 0.5-1.0 part of the kidney bean phytolectins, 1.5-3.0 parts of the tremella polysaccharide, 0.2-2.0 parts of the stachyose or/and raffinose, 0.2-0.5 part of the bletilla gum and 1.0-3.0 parts of the extraction of one kind or more than one kind of scutellaria dry powder, Hollygreen Barberry dry powder and matrine dry powder. The kidney bean phytolectin applications in preparation of people use drugs and the drug composition can be water-soluble complex liquid and is best to be gel, and also can be solid dosage forms such as suppository, disintegrating tablets and the like which are drug dosage forms suitable for external uses. Compared with the prior art, obtained products do not need to be preserved in a low temperature and is long in storage time and convenient to use.
Description
Technical field
The present invention's behaviour technical field of pharmaceuticals.
Background technology
Parasitize the intravaginal micropopulation of healthy women and mainly contain antibacterial, fungus, protozoon and virus.They are mainly dwelt in the mucosa gauffer of vagina and fornix portion, are secondly cervix uteri.The main permanent bacterium of intravaginal has lactobacillus, staphylococcus epidermidis, escherichia coli, corynebacterium, B family streptococcus, streptococcus faecalis, mycoplasma, Candida albicans, dyspepsiacoccus and bacteroid etc.Intravaginal multiple normal microflora falls and host, environment between formed mutual restriction, mutually coordinated, dynamic microecology in vaginas balance.The microecological balance of vagina all plays an important role to maintaining its self purification and host's health.When host is owing to using the sharply decline of broad ectrum antibiotic, ovarian function, the vaginal injury that the factors such as surgical operation, external force and childbirth cause, the reasons such as the excessive use of lonizing radiation and immunosuppressant, cause the habitat of vagina to occur sharply to change, can destroy its microecological balance, cause the dysbacteriosis of vagina.Now very easily cause the infectious disease of vagina, the main source infecting is the conditioned pathogen in microecology in vaginas group, as escherichia coli, bacteroid, dyspepsiacoccus, staphylococcus aureus, B family streptococcus, Candida albicans, infusorian and mycoplasma etc.Vaginal dysbacteriosis main manifestations is various types of vaginitiss.
Be mainly to use the preparation of antibiotic, metronidazole, estrogen and acidify vagina to kill intravaginal pathogenic microorganism for the treatment measure of this type of disease at present, but effect is all undesirable.
Generally recording viable count in healthy women vaginal discharge by the method for quantitative and qualitative analysis is 10
2-9/ ml, the ratio of anaerobe and aerobe is 5:1.Wherein lactobacillus is the permanent bacterium most important in vagina normal flora, quantity is maximum, and its quantity accounts for more than 95%, can reach 8 × 10
7/ ml.Lactobacillus plays an important role maintaining in microecology in vaginas balance, and it can decompose the glycogen in vaginal mucosa epithelial cell, produces a certain amount of lactic acid, makes vagina keep sour environment, is conducive to the self purification of vagina.Simultaneously it can improve the immunologic function of body, and activating macrophage maintains the anti-infection ability of vagina part.In addition it also has the effect that prevents that cervix uteri vagina epitheliumization is raw.(Wang Lisheng, Pan Lingjia, Zhou Dianyuan. Chinese microecology magazine .1 998,10 (5): 300-302.).Utilize prophylactic treatment and the health care to this class illness of microbial ecological agent that the lactobacillus in vagina normal microflora makes to obtain good effect.At present, the preparation that on domestic and international market, existing multiple employing lactobacillus is made is as raw in determined monarch, lactobacillus capsule etc.But because viable bacteria body need to be preserved at low temperatures, the resting period is short, for practical application inconvenience, particularly out of town trip etc.
Application number is that 2011101840614 Chinese patent document has been announced " a kind of human body external compound preparation and uses thereof ", and its first inventor is the first inventor of present patent application namely.This compound preparation, taking phytohemagglutinin (PHA) and tremella polysaccharide as active component, plays contraception, prevents and treats sexually transmitted disease (STD) and lubricated, and its effect is not to increase lactobacillus quantity in woman vagina to maintain microecological balance.
Summary of the invention
Object of the present invention: provide Semen Phaseoli Vulgaris phytohemagglutinin to use application and the pharmaceutical composition thereof in medicine preparation people, Main Function is to increase lactobacillus quantity in woman vagina, maintains microecological balance, and product does not need to preserve at low temperatures, resting period is long, easy to use.
Purposes invention is characterised in that Semen Phaseoli Vulgaris phytohemagglutinin as active component for the preparation of the medicine that increases lactobacillus quantity in woman vagina.And the weight content of Semen Phaseoli Vulgaris phytohemagglutinin is preferably the one thousandth of medicine gross weight.
Pharmaceutical composition of the present invention is taking Semen Phaseoli Vulgaris phytohemagglutinin, tremella polysaccharide, stachyose or/and cottonseed sugar, Bletilla glucomannan as active component, relative weight share in compositions between contained above-mentioned active component is: 0.5～1.0 part of Semen Phaseoli Vulgaris phytohemagglutinin, 1.5～3.0 parts of tremella polysaccharides, stachyose is or/and 0.2～2.0 part of cottonseed sugar, 0.2～0.5 part of Bletilla glucomannan; Or taking Semen Phaseoli Vulgaris phytohemagglutinin, tremella polysaccharide, stachyose or/and cottonseed sugar, Bletilla glucomannan, Radix Scutellariae extract, Radix Berberidis extract, Radix Sophorae Flavescentis extract as active component, relative weight share in compositions between contained above-mentioned active component is: 0.5～1.0 part of Semen Phaseoli Vulgaris phytohemagglutinin, 1.5～3.0 parts of tremella polysaccharides, stachyose is or/and 0.2～2.0 part of cottonseed sugar, 0.2～0.5 part of Bletilla glucomannan, the extract of totally 1.0～3.0 parts of gained of one or more in Radix Scutellariae dry powder, Radix Berberidis dry powder and Radix Sophorae Flavescentis dry powder.Said Semen Phaseoli Vulgaris phytohemagglutinin can be Semen Phaseoli Vulgaris phytohemagglutinin, can be also red kidney bean phytohemagglutinin.
The extract of said Radix Scutellariae, Radix Berberidis and the Radix Sophorae Flavescentis dry powder gained extract that preferably water extraction produces, warm extraction method during these Chinese medicinal plant extracts all adopt in the time extracting, in leaching process, temperature maintains between 40～60 DEG C all the time.
The dosage form of natural drug composition of the present invention can be water miscible complex liquid, is wherein preferably gel; Also can be solid dosage forms be suitable for the pharmaceutical dosage form of external as suppository, disintegrating tablet etc.
Natural drug composition of the present invention is mainly used in increasing lactobacillus quantity in woman vagina, but also can be used for the control of other illness of human body, as the treatment of wound etc.
Natural drug composition coagulant liquid of the present invention is characterised in that and in 100ml coagulant liquid, contains following component:
0.5～1.0 gram of Semen Phaseoli Vulgaris phytohemagglutinin,
1.5～3.0 grams of tremella polysaccharides,
Stachyose is or/and 0.5～2.0 gram of cottonseed sugar,
0.2～0.5 gram of Bletilla glucomannan,
0.8～0.9 gram of NaCl,
PH buffer agent is coagulant liquid acceptable amount pharmaceutically,
Stabilizing agent is coagulant liquid acceptable amount pharmaceutically,
Antiseptic is coagulant liquid acceptable amount pharmaceutically;
Or in 100ml coagulant liquid, contain following component:
0.5～1.0 gram of Semen Phaseoli Vulgaris phytohemagglutinin,
1.5～3.0 grams of tremella polysaccharides,
Stachyose is or/and 0.5～2.0 gram of cottonseed sugar,
0.2～0.5 gram of Bletilla glucomannan,
One or more in Radix Scutellariae dry powder, Radix Berberidis dry powder and Radix Sophorae Flavescentis dry powder water extract of totally 1.0～3.0 grams of gained,
0.8～0.9 gram of NaCl,
PH buffer agent is coagulant liquid acceptable amount pharmaceutically,
Stabilizing agent is coagulant liquid acceptable amount pharmaceutically,
Antiseptic is coagulant liquid acceptable amount pharmaceutically.
Said Semen Phaseoli Vulgaris phytohemagglutinin can be Semen Phaseoli Vulgaris phytohemagglutinin, can be also red kidney bean phytohemagglutinin.
Medicaments compound is the pathological state for body, emphasizes organic cooperation of each component and consumption, carries out multiple location, many target spots, multipath comprehensive adjustment, thereby the poised state of recovery body.
Natural drug composition emphasis of the present invention is for the lactobacillus in close relations with women's health, adopting is crucial composition from Semen Phaseoli Vulgaris phytohemagglutinin and the oligosaccharide (stachyose is or/and cottonseed sugar) of Semen Phaseoli Vulgaris separation and Extraction, add and join the active ingredient that other extracts from natural product or Chinese herbal medicine, prepare to become and there is the vagina of promotion lactobacillus growth, inhibition and kill harmful microorganism comprise antibacterial, the preparation of the effects such as fungus and virus, and supplementary natural estrogen, protect from infection, repair wound, final realization recovered taking lactobacillus as main naturalness.Prove that through practical application this product is to BV(bacterial vaginosis), VVC(VVC), BP(bowenoid papulosis), HPV(human papillomavirus) and HIV virus all have and suppress and kill function.Product of the present invention optionally promotes one or more probiotics metabolism and breeding, enters the component of host health except containing stachyose and cottonseed sugar etc., also contain phytohemagglutinin, they have obvious facilitation to lactobacillus and Bacillus bifidus breeding.Therefore, product of the present invention is a kind of novel, carries the compound formulation of the PHA of probiotic bacteria " grain ", oligosaccharide and breeding (division) promoter simultaneously, and its action effect is much more obvious than independent prebiotics.
Add oligosaccharide (stachyose is or/and cottonseed sugar) and Bletilla glucomannan, its objective is the repair ability of natural drug composition and the ability in conjunction with skin and mucosa of strengthening; In addition, Bletilla glucomannan itself also has certain bacteriostasis.
Natural drug composition coagulant liquid of the present invention can use like this: under normal circumstances, with containing Radix Scutellariae,
The coagulant liquid (being called for short coagulant liquid A) of Radix Berberidis and Radix Sophorae Flavescentis composition adds water and does daily cleaning nursing; Occur when disease first using coagulant liquid A, in the time that symptom is heavier or use after coagulant liquid A 48h symptom can use the coagulant liquid (being called for short coagulant liquid B) containing Radix Scutellariae, Radix Berberidis and Radix Sophorae Flavescentis composition when alleviating.In experiment below and embodiment, Semen Phaseoli Vulgaris used or red kidney bean phytohemagglutinin are patent applicant's laboratory and extract from Semen Phaseoli Vulgaris that produce in Yunnan and red kidney bean.
The micro-ecology of product of the present invention maintains and the principle that increases lactobacillus quantity is:
1. the pH of solution is 4.0～4.5, great majority is caused to the microorganism of BV has inhibitory action, and this pH value is applicable to the growth of lactobacillus;
2. phytohemagglutinin is a kind of mitogen, we find, Semen Phaseoli Vulgaris phytohemagglutinin can promote lactobacillus growth under above-mentioned formula concentration;
3. in solution, also contain oligosaccharide (stachyose and cottonseed sugar), like this, as the nutrient substance of lactobacillus and lactobacillus is played to the effect of nutritional support;
4. in Semen Phaseoli Vulgaris phytohemagglutinin extracting solution, also contain estrogen Semen Phaseoli Vulgaris isoflavone, relevant studies show that both domestic and external, senile vaginitis patients is used estrogen can reverse the atrophy change of vaginal wall and relief of symptoms, the elasticity of the estrogenic supplementary thickness that increases vagina epithelium, vaginal wall, reduce vaginal pH, recovered the self purification of vagina;
5. phytohemagglutinin can stimulate lymphocyte to produce interferon and interleukin.
Beneficial effect of the present invention: compared to the prior art, products obtained therefrom does not need to preserve at low temperatures, and the resting period is long, easy to use.
Brief description of the drawings
Fig. 1 is the microphotograph of Semen Phaseoli Vulgaris PHA on lactobacter growth impact that shows variable concentrations.
Fig. 2 represents the effect of three test group to scalding healing.
Below by experiment, the invention will be further described.In experiment, method therefor is conventional method if no special instructions.
Extraction, purification and the determination of activity of the agglutinins such as experiment 1, Semen Phaseoli Vulgaris.
(1) extraction of the agglutinin such as Semen Phaseoli Vulgaris and purification adopt the disclosed technology of Chinese patent document that application number is 200910094233.1 to carry out, and protein content adopts general biuret method to measure.
(2) activity of lectin is measured and is adopted the disclosed technology of Chinese patent document that application number is 201110184061.4 to carry out.
The effect of experiment 2, the lactobacillus of Semen Phaseoli Vulgaris phytohemagglutinin to separation and Culture
(in vain) Semen Phaseoli Vulgaris phytohemagglutinin is made into 7 concentration experimental grouies of 0.1,0.2,0.5,1.0,2.0,5.0,10.0 mg/mL and 1 normal saline matched group.To be attached in the MRS solid medium that is coated with lactobacillus containing variable concentrations Semen Phaseoli Vulgaris phytohemagglutinin filter paper (d=6 mm) with scraps of paper development method, 4 parallel group of each concentration, cultivates in 37 DEG C of constant incubators.Every 12 h observe a lactobacillus and breed situation Taking Pictures recording, cultivate 72 h and finish.Repeat to test three times.The impact of observation and analysis Semen Phaseoli Vulgaris phytohemagglutinin on lactobacillus propagation.
Cultivate by MRS culture medium: tested material (the Semen Phaseoli Vulgaris phytohemagglutinin that is respective concentration is dissolved in the normal saline) filter paper (d=6 mm) that adopts scraps of paper development method that Semen Phaseoli Vulgaris phytohemagglutinin concentration is respectively to 0.0,0.1,0.2,0.5,1.0,2.0,5.0,10.0 mg/mL is attached in 90 mm glass culture dishs of the MRS solid medium that scribbles lactobacillus, in 37 DEG C of constant incubators, cultivate, wherein 0 mg/mL group is blank group.Observe a lactobacillus every 12 h and breed situation Taking Pictures recording result, cultivate 72 h and finish, analyze the impact of Semen Phaseoli Vulgaris phytohemagglutinin on lactobacillus growth and propagation.Each experiment has 4 Duplicate Samples, and experiment in triplicate.
Lactobacillus is cultivated after 12 h, there is a small amount of macrocolony to form around containing the filter paper of 1.0 mg/mL Semen Phaseoli Vulgaris phytohemagglutinin groups, and matched group and all the other each dosage group filter papers are around without obviously macrocolony appearance, show that 1.0 mg/mL Semen Phaseoli Vulgaris phytohemagglutinin groups have facilitation to lactobacillus growth and breeding at first.Fig. 1 is that lactobacillus is cultivated the microphotograph after 12 h, the impact of the Semen Phaseoli Vulgaris phytohemagglutinin of expressing variable concentrations on lactobacillus growth: a is matched group, and b is 0.1 mg/mL group, and c is 0.5 mg/mL group, d is 1.0 mg/mL groups, and e is 5.0 mg/mL groups.
Experiment 3, Semen Phaseoli Vulgaris phytohemagglutinin are to the growth promoting function at body vagina lactobacillus
It is formulated that degree this test of agglutinin tested material is that Semen Phaseoli Vulgaris phytohemagglutinin adds 3% tremella polysaccharide, and the content of Semen Phaseoli Vulgaris phytohemagglutinin is 40mg/ml; Tester is adjuvant, does not contain the tremella polysaccharide liquid of phytohemagglutinin.The pH value of phytohemagglutinin liquid and adjuvant is 4.5.
Experimental animal is 4 of Female rabbits, body weight 2.0～2.5 kg, all sub-cage rearing.20 DEG C of left and right of laboratory temperature.
Test basis: in Ministry of Public Health " disinfection technology standard, the third edition, the first fascicle, experimental technique specification " (version in 1999) the 3.8th article.The method of inspection: PHA group, adjuvant matched group are set.To animal label, 1 is matched group, and 2,3,4 is PHA group, the sterilizing cotton sliver that PHA group is got suitable size soaks the tested material with 0.5ml, inserts in rabbit vagina, and the sterilizing cotton sliver that adjuvant matched group is got formed objects soaks with adjuvant, contact with vaginal mucosa, within every 24 hours, give a medicine, continue medication 7 days.
Before administration, getting rabbit vagina liquid and in MRS culture medium, cultivate observation, was after administration finishes after 7 days, then got tested material group and matched group rabbit vagina liquid is cultivated observation in respectively at MRS culture medium, relatively vagina Flora dynamics before and after administration.
Before administration, the bacterium colony adularescent yeast in culture medium and lactobacillus bacterium colony.After administration, in culture medium corresponding to tested material group, be a large amount of lactobacilluss, and still occur some lactobacilluss and yeast bacterium colony in culture medium corresponding to adjuvant group.
Experiment 4, Semen Phaseoli Vulgaris phytohemagglutinin and red kidney bean phytohemagglutinin are on escherichia coli, staphylococcus aureus, beads pearl bacterium, saccharomycetic impact
Adopt respectively nutrient agar, potato glucose culture medium, sabouraud culture medium is cultivated.Adopt conventional preparation, sterilization to make above-mentioned culture medium.Inoculate respectively escherichia coli, staphylococcus aureus, candidiasis, yeast.In plate, place again the sterilizing filter paper of diameter 6mm, on filter paper, drip the Semen Phaseoli Vulgaris phytohemagglutinin of the filtration sterilization of variable concentrations.Drip normal saline according to group.Be placed in 37 DEG C of couveuses and cultivate 36h.The results are shown in Table 1 and table 2.
The impact of table 1 Semen Phaseoli Vulgaris phytohemagglutinin on four kinds of bacterium
" 0 " indicates bacteriostasis."+" indicates without bacteriostasis.
The impact of table 2 red kidney bean phytohemagglutinin on four kinds of bacterium
" 0 " indicates bacteriostasis."+" indicates without bacteriostasis.
Experiment 5, containing Semen Phaseoli Vulgaris and the impact of red kidney bean phytohemagglutinin coagulant liquid on escherichia coli, staphylococcus aureus, yeast, beads pearl bacterium of Chinese medicine ingredients
The tested material formula that this experiment is used is as follows:
In 100ml coagulant liquid, contain following component:
Semen Phaseoli Vulgaris phytohemagglutinin is respectively 0.5 gram by high, medium and low concentration, and 0.1 gram, 0.05 gram and 0.01 gram, or red kidney bean phytohemagglutinin is respectively 0.5 gram by high, medium and low concentration, and 0.1 gram, 0.05 gram and 0.01 gram,
Stachyose is or/and cottonseed sugar is respectively 2.0 grams,
1.5 grams of tremella polysaccharides,
0.2 gram of Bletilla glucomannan,
The water extract of 1.0 grams, Radix Scutellariae dry powder, 1.0 grams, Radix Berberidis dry powder and 1.0 grams of gained of Radix Sophorae Flavescentis dry powder,
0.9 gram of NaCl,
PH buffer agent: be acetic acid-sodium-acetate buffer (pH4.5), get 1.8 grams of sodium acetates, add glacial acetic acid 0.98ml, then be diluted with water to 100ml, to obtain final product.
4,000 2.0 grams of stabilizing agent: PEG,
Antiseptic: 0.3 gram of potassium sorbate.
PH is 0.45.
Experimental technique is with experiment 4.Adopt respectively nutrient agar, potato glucose culture medium, sabouraud culture medium is to escherichia coli and staphylococcus aureus, and yeast and beads pearl bacterium are cultivated.
Adopt conventional preparation, sterilization makes above-mentioned culture medium.Inoculate respectively escherichia coli, staphylococcus aureus, candidiasis, yeast.In plate, place again the sterilizing filter paper of diameter 6mm, on filter paper, drip Semen Phaseoli Vulgaris phytohemagglutinin and three kinds of coagulant liquids that Chinese medicine extract is mixed with of variable concentrations.
Drip normal saline according to group.Be placed in 37 DEG C of couveuses and cultivate 36h.The results are shown in Table 3 and table 4.
Table 3 is the impact on four kinds of bacterium containing the Semen Phaseoli Vulgaris agglutinin coagulant liquid of Chinese medicine extract
Note: " 0 " indicates bacteriostasis.
Table 4 is the impact on four kinds of bacterium containing the red kidney bean agglutinin B gel of Chinese medicine extract
Note: " 0 " indicates bacteriostasis.
Experiment 6, containing the Semen Phaseoli Vulgaris agglutinin coagulant liquid of Chinese medicine extract to mycoplasma and chlamydial killing action
The concrete formula of medicinal liquid (coagulant liquid) is as follows:
0.5 gram of Semen Phaseoli Vulgaris phytohemagglutinin,
2.0 grams of tremella polysaccharides,
Oligosaccharide (stachyose and cottonseed sugar) is 0.5g altogether,
0.2 gram of Bletilla glucomannan,
The water extract of 1.0 grams, Radix Scutellariae dry powder, 1.0 grams, Radix Berberidis dry powder and 1.0 grams of gained of Radix Sophorae Flavescentis dry powder,
NaCl:0.85 gram,
PH buffer agent: be acetic acid-sodium-acetate buffer (pH4.5), get 1.8 grams of sodium acetates, add glacial acetic acid 0.98ml, then be diluted with water to 100ml, to obtain final product.
4,000 2.0 grams of stabilizing agent: PEG,
Antiseptic: 0.3 gram of potassium sorbate.
PH value is 4.5.
" mycoplasma (Uu/Mh) the separation and Culture susceptibility test kit " that experiment adopts Zhuhai Dier Bioengineering Co., Ltd. to produce, operates by operation instructions.At 37 DEG C of incubators cultivations 24 and 48h.Method sees the following form 5.
Table 5 culture medium and medicinal liquid scale
Positive inoculation liquid has infected mycoplasma and/or chlamydial culture fluid.
Step: get respectively the positive inoculation liquid of bottle 100 μ l, 20 μ l, 20 μ l, 20 μ l add respectively the culture medium of 390 μ l, 160 μ l, 120 μ l and 180 μ l by low middle height and blank dosage, then add respectively 10 μ l, 20 μ l, 30 μ l and 0 μ l medicinal liquid to enter test tube.Add again about 1ml paraffin oil, cultivate in 37 degrees Celsius.
Result shows, observes through 24h, adds low dosage medicinal liquid to fail suppress or kill mycoplasma or chlamydia.And add middle and high dosage medicinal liquid can suppress or kill mycoplasma and/or chlamydia.After 48h, the more taint-free culture fluid that added middle and high dosage medicinal liquid is transferred in fresh culture, through 24h and 48h, until 72h observes culture medium color without any variation.Therefore experimental result can illustrate that the middle and high dosage of coagulant liquid can kill mycoplasma.
Embodiment 1, formula A.In 100 milliliters of coagulant liquids, contain:
0.5 gram of Semen Phaseoli Vulgaris phytohemagglutinin,
2.0 grams of tremella polysaccharides,
Oligosaccharide (total amount of stachyose and cottonseed sugar) 0.5g
0.2 gram of Bletilla glucomannan
0.85 gram of NaCl,
PH buffer agent: be acetic acid-sodium-acetate buffer (pH4.5), get 1.8 grams of sodium acetates, add glacial acetic acid 0.98ml, then be diluted with water to 100ml, to obtain final product,
4,000 2.0 grams of stabilizing agent: PEG,
Antiseptic: 0.3 gram of potassium sorbate,
PH value is 4.5.
0.5～2.0ml coagulant liquid, the 100～200ml that adds water, can be used for the daily nursing of women's V&V to clean.Through the actual use of many people, every day 1～2 time, reduce leucorrhea abnormal, eliminate the ill symptoms successfuls such as abnormal flavour and pruritus.
Embodiment 2, formula A basis on add again Radix Berberidis, the extract of Radix Scutellariae or Radix Sophorae Flavescentis etc., become formula B.Formula B for to contain in 100 milliliters of coagulant liquids:
0.5 gram of phytohemagglutinin,
2.0 grams of tremella polysaccharides,
Oligosaccharide (total amount of stachyose and cottonseed sugar) 0.5g,
0.2 gram of Bletilla glucomannan,
Each 1.0 grams of Radix Scutellariae dry powder, Radix Berberidis dry powder and Radix Sophorae Flavescentis dry powder, the water extract of totally 3.0 grams of gained,
0.85 gram of NaCl,
PH buffer agent: citric acid-sodium hydrogen phosphate buffer (pH4.0).First liquid: get citric acid 21g or anhydrous citric acid 19.2g, add water and make to be dissolved into 1000ml, put in refrigerator and preserve.Second liquid: get sodium hydrogen phosphate 71.63g, adding water makes to be dissolved into 1000ml. and get above-mentioned first liquid 61.45ml and mix with second liquid 38.55ml, shakes up, to obtain final product,
Stabilizing agent: 3.0 grams of mannose,
Antiseptic: 0.15 gram, ethyl ester sodium,
PH value is 4.5-4.7.
Embodiment 3, treatment to vagina
Press the A formula of embodiment 1, in the time there is vagina, by each 2～3ml, inject vagina.Every day 1～2 time.It is more than therapeutic dose.After 48 hours, observe, if the Shi Zeying that is not clearly better adopts the formula B of embodiment 2.Satisfied to the therapeutic effect of vagina.
Embodiment 4, to mycoplasma or chlamydial treatment
In the time that medical diagnosis is defined as woman vagina or pudendum mycoplasma or chlamydia infection, or the vagina that causes of other reason, process while not improving after 48 hours through the formula A of embodiment 1, can adopt embodiment 2 B that fills a prescription to process.Consumption is every day 2～3 times, each 3～5mL.After using 3～7 days continuously, through statistical analysis, effective percentage 100%, obvious effective rate 82%, cure rate 65～70%.
Embodiment 5, to HPV(human papillomavirus) therapeutical effect
Patient revives so-and-so, female, 25 years old.Symptom is that pudendum is black pathological changes, pruritus, and vaginal secretions is thickness sample, and cervix uteri is smooth.Getting secretions send " Jin Yu inspection body " to test.Related check report explanation: " second filial generation hybrid capture technology (HC2) that this experiment adopts U.S. FDA to ratify can detect 16,18,31,33,35,39,45,51,52,56,58,68 totally 13 kinds of high-risk hypotype HPV simultaneously ".Positive (the result (test ratio=3600(reference value is normal ratio <1.00) of assay: HPV-DNA.Diagnosis: HPV infects (positive).
Treatment: give interleukin 6 0IU intramuscular injection, biweekly.Vagina gives gel B and the interferon suppository of embodiment 2, is used alternatingly.Gel B consumption is every day 2～3 times, each 3～5ml, weekly administration 5 days.Pruritus vulvae symptom is alleviated after three weeks, and (leep knife) treatment of performing the operation of external dark and gloomy color lesion, continues vagina administration subsequently, takes valaciclovir check afterwards in 27 days after 6 weeks, and HPV-DNA value is reduced to 366.Continue to use gel B surrounding, HPV-DNA value detects negative (being reduced to 0.1).Rehabilitation.
Embodiment 6, effect to herpes zoster
Patient: model so-and-so, man, 55 years old.At the beginning of 2012 4 months, start to occur blister shape herpes, the about 6cm of area owing to toiling away at the right hand palm back side
2,.After about 10 days, herpes starts to break and trickle, follows pain.Then hospital treatment, is admitted to hospital 10 days, and intravenous injection and antiviral agents for oral use be as acyclovir, the additional interferon of smearing.After leaving hospital, continue to smear interferon, use 10 after effect still bad.Then use the gel B of similar embodiment 2 instead, distinguish as without Radix Sophorae Flavescentis composition, the amount of Radix Scutellariae and Radix Berberidis water extract changes the water extract of 1.5 grams, dry powder separately into.Use this gel to smear.Every day 4～5 times, each approximately 1.0ml.Use 10 days left and right herpess to fully recover, painless.Compared with interferon, this gel curative effect is obvious, and has analgesic effect.
Embodiment 7, effect to general traumatic injury of skin
Skin to common mechanical and muscle injury, as wound foreign etc., can directly use the B component gel containing PHA.With embodiment 7.There is rapid hemostasis, protect from infection and the effect of accelerating wound.Contrast positive drug matched group can accelerating wound speed approximately 3 days.
Embodiment 8, to scald Healing
The scalding model of skin: select 24 S-129 mices, remove the hair-fields of both sides, back apart from the spinal column 5mm about 20mm × 20mm in place after anesthesia, by temperature about 120 DEG C in the centre of hair-fields, the electrinic iron flicking that the diameter of perming is 10mm 6 seconds, causes II degree to scald.(Liu Yi, Su Zhihong. the impact [J] of EGF on the dark II degree of mice scalding model wound healing. Beijing Military Area Command's medicine. 2000,12(6); Zhong Weitian, Hua He and, Zhong Xiwen. quick-acting burn cream is scalded the therapeutical effect [J] of Cavia porcellus to dark II degree. China's burn magazine. 2006,22(4) .).
Process: another group wound YUNNAN BAIYAO solution erasing (matched group) of A component Semen Phaseoli Vulgaris phytohemagglutinin solution erasing (experimental group) of same embodiment 1 of one group of wound, the 3rd group of wound do not deal with (blank group), due to the feature of mice life habit, all wounds are not wrapping all, smear medicine once to wound every day, discontinues medication when having wound to start desquamation.
Wound surface situation of change: test the 2nd day, Jiao who respectively forms face organizes disappearance in vain, becomes redness.The 3rd day, the face of respectively forming showed to be all peony, and formed the very hard thick shell of one deck on its surface.The 4th day, respectively form face complexion changed black, test group and matched group start to occur healing state.The 5th day, the duricrust edge perk of the most of wound surface of test group.The 7th day, the duricrust of most of wound surface of test group came off, and formed the softer shell of one deck in wound surface, and the shell of matched group and blank group wound surface is still very firmly very thick.The 13rd day, the wound of experimental group and matched group healed substantially, and the wound of blank group is also not healing all.The 15th day, the wound of experimental group and matched group all healed, the wound of blank group is also no healing all.Wound surface diameter measurement the results are shown in Table 6.
The wound surface diameter of different number of days after table 6 scald group wound
Processed through spss 11.5 by table 2 data, the p=0.043 ﹤ 0.05 of experimental group and matched group, illustrate significant difference; The p=0.026 ﹤ 0.05 of experimental group and blank group, illustrates significant difference.
As shown in Figure 2, three groups of effects to scalding healing are respectively the blank group of experimental group > matched group >, illustrate that thus Semen Phaseoli Vulgaris phytohemagglutinin has obvious facilitation to the healing of scalding.
Claims (3)
1. Semen Phaseoli Vulgaris phytohemagglutinin, preparation people with the application in medicine, is characterized in that: using Semen Phaseoli Vulgaris phytohemagglutinin as active component for the preparation of the medicine that increases lactobacillus quantity in woman vagina.
2. a pharmaceutical composition, is characterized in that:
Taking Semen Phaseoli Vulgaris phytohemagglutinin, tremella polysaccharide, stachyose or/and cottonseed sugar, Bletilla glucomannan as active component, relative weight share between active component is: 0.5～1.0 part of Semen Phaseoli Vulgaris phytohemagglutinin, 1.5～3.0 parts of tremella polysaccharides, stachyose is or/and 0.2～2.0 part of cottonseed sugar, 0.2～0.5 part of Bletilla glucomannan;
Or taking Semen Phaseoli Vulgaris phytohemagglutinin, tremella polysaccharide, stachyose or/and cottonseed sugar, Bletilla glucomannan, Radix Scutellariae extract, Radix Berberidis extract, Radix Sophorae Flavescentis extract as active component, relative weight share between active component is: 0.5～1.0 part of Semen Phaseoli Vulgaris phytohemagglutinin, 1.5～3.0 parts of tremella polysaccharides, stachyose is or/and 0.2～2.0 part of cottonseed sugar, 0.2～0.5 part of Bletilla glucomannan, the extract of totally 1.0～3.0 parts of gained of one or more in Radix Scutellariae dry powder, Radix Berberidis dry powder and Radix Sophorae Flavescentis dry powder.
3. pharmaceutical composition as claimed in claim 2, is characterized in that for gel, contains following component in every 100ml coagulant liquid:
0.5～1.0 gram of Semen Phaseoli Vulgaris phytohemagglutinin,
1.5～3.0 grams of tremella polysaccharides,
Stachyose is or/and 0.5～2.0 gram of cottonseed sugar,
0.2～0.5 gram of Bletilla glucomannan,
NaCl0.8～0.9 gram,
PH buffer agent is coagulant liquid acceptable amount pharmaceutically,
Stabilizing agent is coagulant liquid acceptable amount pharmaceutically,
Antiseptic is coagulant liquid acceptable amount pharmaceutically;
Or in every 100ml coagulant liquid, contain following component:
0.5～1.0 gram of Semen Phaseoli Vulgaris phytohemagglutinin,
1.5～3.0 grams of tremella polysaccharides,
Stachyose is or/and 0.5～2.0 gram of cottonseed sugar,
0.2～0.5 gram of Bletilla glucomannan,
One or more in Radix Scutellariae dry powder, Radix Berberidis dry powder and Radix Sophorae Flavescentis dry powder water extract of totally 1.0～3.0 grams of gained,
NaCl0.8～0.9 gram,
PH buffer agent is coagulant liquid acceptable amount pharmaceutically,
Stabilizing agent is coagulant liquid acceptable amount pharmaceutically,
Antiseptic is coagulant liquid acceptable amount pharmaceutically.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310056588.8A CN103157095B (en) | 2013-02-22 | 2013-02-22 | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310056588.8A CN103157095B (en) | 2013-02-22 | 2013-02-22 | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103157095A CN103157095A (en) | 2013-06-19 |
| CN103157095B true CN103157095B (en) | 2014-09-17 |
Family
ID=48580960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310056588.8A Active CN103157095B (en) | 2013-02-22 | 2013-02-22 | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103157095B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103920140B (en) * | 2014-05-04 | 2016-06-08 | 云南康洲生物科技有限公司 | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation |
| CN107213453B (en) * | 2017-06-21 | 2020-07-14 | 云南康洲生物科技有限公司 | Abortion medicine |
| CN108404111B (en) * | 2017-12-25 | 2020-04-28 | 云南康洲生物科技有限公司 | A bacteriostatic and antiviral preparation containing semen Phaseoli vulgaris phytohemagglutinin as main ingredient |
| CN109674671A (en) * | 2019-01-07 | 2019-04-26 | 广州市拓瑞科技有限公司 | The preparation method of vaginal care composition object and its application and the women secret conditioning liquid comprising it and women secret conditioning liquid |
| CN110755601B (en) * | 2019-10-31 | 2023-06-23 | 云南康洲生物科技有限公司 | Kidney bean lectin plant medicine composition for treating HIV/AIDS immune reconstruction defect and preparation method and application thereof |
| CN111450235A (en) * | 2020-06-05 | 2020-07-28 | 杨正东 | Contraceptive gel jelly |
-
2013
- 2013-02-22 CN CN201310056588.8A patent/CN103157095B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| 植物血凝素在防控畜禽疾病中的应用;陈元坤等;《兽医导刊》;20111231(第6期);38-40 * |
| 殷晓丽等.豆科凝集素研究进展.《中国生物工程杂志》.2011,第31卷(第7期),133-139. |
| 豆科凝集素研究进展;殷晓丽等;《中国生物工程杂志》;20111231;第31卷(第7期);133-139 * |
| 陈元坤等.植物血凝素在防控畜禽疾病中的应用.《兽医导刊》.2011,(第6期),38-40. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103157095A (en) | 2013-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2609754C (en) | Compositions of benzoic acid and saccharides for regulating and maintaining bacterial flora and acidity in the vagina | |
| CN103157095B (en) | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof | |
| CN1251763A (en) | Process for preparing Chinese medicine 'Qianjin tablets' for treating gynopathy | |
| CN102727531A (en) | Active lactic acid bacteria capsules with treatment and prevention effect on vaginitis | |
| CN115607577B (en) | Probiotics with efficacy of relieving stomatitis, and preparation method and application thereof | |
| CN109985069B (en) | Probiotic compositions and uses thereof | |
| CN101797269B (en) | Physiological balance liquid for adjusting microecology in vaginas of women | |
| CN103251844B (en) | For the tablet of cleaning throat and moistening larynx | |
| CN101690734B (en) | Lactobacillus vaginal capsule and preparation method thereof | |
| CN113274414A (en) | Probiotics preparation for repairing and maintaining vaginal microecological balance | |
| CN103520262B (en) | A kind of lipid soluble gynecological gel | |
| CN109771595A (en) | A kind of Chinese medicine composition and preparation method thereof for treating gynaecological imflammation | |
| CN103599437B (en) | One treats colpitic traditional Chinese medicine liquid | |
| CN103251845B (en) | For the compositions of cleaning throat and moistening larynx | |
| CN111759852A (en) | Pharmaceutical composition for vagina, pharmaceutical preparation, preparation method and application thereof | |
| CN108785383A (en) | A kind of antibacterial gynecology externally used pharmaceutical combination and the preparation method and application thereof | |
| CN103961585A (en) | Medicament for treating postpartum nonspecific vaginitis and preparation method thereof | |
| CN101953879B (en) | Microecological preparation for quickly and efficiently preventing and treating swine high fever | |
| CN115873777A (en) | Oriented domestication modified probiotics, microecological preparation containing probiotics and application of probiotics in gynecological inflammation | |
| CN107837274A (en) | A kind of purposes of diet fiber composition | |
| CN104208194A (en) | Traditional Chinese medicine composition for treating bovine endometritis, preparation method and application thereof | |
| CN114015727A (en) | Peptide extract, peptide extract mixed solid beverage, peptide extract essence and application | |
| CN105106475A (en) | Traditional Chinese medicine gel used for treating toxin-accumulating rotting and ulcerating type bedsores during clinical nursing | |
| CN105079482B (en) | A kind of Chinese medicine external gel treating the companion's infection of serious decubital ulcer and preparation method thereof | |
| CN109771635A (en) | A kind of preparation method adjusting women Bacillus acidi lactici microecological balance Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |